Published on
February 27, 2020
- 12:00 GMT
Athenex, Inc. Reports Fourth Quarter and Year Ended December 31, 2019 Financial Results and Provides Corporate Update
Tirbanibulin ointment NDA for actinic keratosis was submitted Oral Paclitaxel NDA submission is on track; Final FDA meeting scheduled for early April Presentation of Oral Paclitaxel Phase 3 results at SABCS received broad positive reception 43% y/y …
Distribution channels:
